Author

Laurent Biroulet 1

1 University Hospital, Nancy, France

COSTS DRUG SAVINGS USING A TEST-BASED STRATEGY VERSUS AN EMPIRIC DOSE ESCALATION IN PATIENTS WITH CROHN’S DISEASE LOOSING RESPONSE TO ANTI-TNF THERAPY

Xavier Roblin, Michel Lamure, Alain Attar, Bernard Savarieau, pierre brunel, Laurent Biroulet

DEVELOPMENT OF AN ALGORITHM INCORPORATING PHARMACOKINETICS OF ADALIMUMAB IN INFLAMMATORY BOWEL DISEASES

Xavier Roblin, Melanie Rinaudo, Emilie Del Tedesco, Laurent Biroulet, Stéphane Paul

FAECAL CALPROTECTIN MEASUREMENT AND INFLIXIMAB TROUGH LEVELS PREDICT THERAPEUTIC EVOLUTION CD PATIENTS IN CLINICAL REMISSION.

Xavier Roblin, gerard duru, lea clavel, Emilie Del Tedesco, Jean Marc Phelip, Laurent Biroulet, Stéphane Paul

INFLIXIMAB DE-ESCALATION BASED ON TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE PATIENTS: A PROOF-OF CONCEPT STUDY

Stéphane Paul, Xavier Roblin, Laurent Biroulet

INFLIXIMAB TROUGH LEVEL THRESHOLDS VARY DEPENDING ON THE EFFICACY CRITERION CHOSEN IN IBD PATIENTS

Xavier Roblin, camille jarlot, Emilie Del Tedesco, Jean Marc Phelip, Laurent Biroulet, Stéphane Paul

INTEREST OF COMBINATION THERAPY WITH IMMUNOSUPPRESSIVE TREATMENT IN IBD PATIENTS IN LOSS OF RESPONSE TO INFLIXIMAB AND EXHIBITING VERY HIGH ANTI-INFLIXIMAB ANTIBODY (ATI) LEVELS.

Xavier Roblin, Emilie Del Tedesco, Laurent Biroulet, Stéphane Paul

PERSISTENCE OF ANTIBODIES TO INFLIXIMAB FOR MORE THAN TWO MONTHS STRONGLY PREDICTS LOSS OF RESPONSE TO INFLIXIMAB IN INFLAMMATORY BOWEL DISEASES

manon leclerc, Stéphane Paul, hubert marotte, Emilie Del Tedesco, Laurent Biroulet, Xavier Roblin

Item 1 - 7 / 7
1